Oxford/AstraZeneca Third Booster Strong Enough Against COVID-19 Variants, Study Shows: FT

Oxford University and AstraZeneca Plc's AZN COVID-19 vaccine works well as a third booster shot, according to a study, the Financial Times reported citing people familiar with the matter.
A third booster shot showed "strong enough against any variant," despite concern that the immune system might fight off the adenovirus used as a delivery mechanism.
Some scientists have feared that repeated use of the adenovirus vector - an inactivated cold virus - could stop the immune system from recognizing the virus's spike protein.
However, the study found the participants' immune systems reacted to the adenovirus used to deliver the protein. Still, it had a far more significant reaction to the protein, according to the FT.
It is not known when Oxford and AstraZeneca plan to publish study data, the paper added.
Price Action: AZN shares are up 0.21% at $56.11 during the premarket session on the last check Wednesday.

Overview Rating:

Speculative

0100